Statement: A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2.
Primary_evidence: Adverse Events 1:   Total: 15/41 (36.59%)   Febrile neutropenia * 0/41 (0.00%)   Diarrhea * 1/41 (2.44%)   Stomach pain * 1/41 (2.44%)   Fever * 2/41 (4.88%)   Cytokine release syndrome * 1/41 (2.44%)   Infection * 1/41 (2.44%)   Skin infection * 2/41 (4.88%)   Urinary tract infection * 1/41 (2.44%)   Coagulopathy * 0/41 (0.00%)   INR increased * 0/41 (0.00%)   Lipase increased * 1/41 (2.44%) Adverse Events 2:   Total: 2/5 (40.00%)   Febrile neutropenia * 1/5 (20.00%)   Diarrhea * 0/5 (0.00%)   Stomach pain * 0/5 (0.00%)   Fever * 0/5 (0.00%)   Cytokine release syndrome * 0/5 (0.00%)   Infection * 0/5 (0.00%)   Skin infection * 0/5 (0.00%)   Urinary tract infection * 0/5 (0.00%)   Coagulopathy * 1/5 (20.00%)   INR increased * 1/5 (20.00%)   Lipase increased * 0/5 (0.00%)